SOTIO
Manufacturing · Czech Republic · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1518/2 Jankovcova 7, Prague, Praha, Czec...Phone Number
+420 224175111Website
www.sotio.comRevenue
$13.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About SOTIO
SOTIO is focused on developing next-generation immunotherapies for cancer patients, with a robust pipeline of both internally developed and in-licensed candidates for various solid tumor types. The company aims to create safer and more effective treatments through rigorous clinical development, emphasizing immunocytokines, cell therapies, and antibody-drug conjugates. SOTIO is dedicated to translating innovative science into tangible patient benefits and is actively seeking to expand its portfolio with promising oncology projects at advanced stages. Their target clients are individuals affected by solid tumors who can benefit from advanced cancer therapies.Explore more
SOTIO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SOTIO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when SOTIO launches new products
Earning: See what the market has to say on SOTIO recently announced quarterly report
Check out if SOTIO is spiking on competitors!
Check if SOTIO has recently received funding, and reach out quickly before it becomes old news!
Click to see if SOTIO had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once SOTIO has new funding data
Congratulate Masked Content for being promoted to Masked Content at SOTIO
Website visits: Recent activity has been detected on your website
SOTIO, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined SOTIO as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
SOTIO is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SOTIO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SOTIO.
SOTIO financials insights
Gather financial insights about SOTIO, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Other Financing Round
$316.5M
SOTIO Tech Stack
A closer look at the technologies used by SOTIO
See more technologies
Most Recent Scoops
Promotion
Executive Move
Vivi Boura has been promoted from Deputy Chief Medical Officer to the role of Chief Medical Officer.
Executive Moves, Promotion
Person-Based
Person-Based
Person-Based
Person-Based
SOTIO News & Media
SOTIO promotes Vivi Boura to CMO role | The Pharmaletter
SOTIO Biotech, a Czech clinical-stage biopharma owned by PPF Group, today announced the promotion of Dr Vivi Boura, an accomplished oncologist with extensive experience leading the clinical development of novel cancer therapies, to chief medical officer (CMO).SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments
PRAGUE & BASEL, Switzerland & BOSTON--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, this week presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. Preclinical data on SOT109 (anti-CDH17 ADC) and SOT106 (anti-LRRC15 ADC) demonstrate strong anti-tumor activity and favorable tolerability profiles across multiSOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting
PRAGUE & BASEL, Switzerland & BOSTON--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid tumors, showcasing advancements in its innovative pipeline. The presentations will take place at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL from April 25-30, 2025. SOT106 is being developed for the treatmSOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113
PRAGUE & AMSTERDAM--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix B.V. (“Synaffix”), a Lonza company (SWX: LONN), to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs. The exercised option will enable SOTIO to advance two bispecific candidates, designed by its in-house research team, that
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SOTIO
Sign Up For FreeTo access detailed company insights
SOTIO is focused on developing next-generation immunotherapies for cancer patients, with a robust pipeline of both internally developed and in-licensed candidates for various solid tumor types. The company aims to create safer and more effective treatments through rigorous clinical development, emphasizing immunocytokines, cell therapies, and antib... Read More
